Founded by Kian Sadeghi, Nucleus Genomics offers a consumer and clinic-facing platform built on whole-genome sequencing rather than narrow SNP chips. Customers send a saliva sample, and Nucleus analyzes the resulting genome with proprietary AI polygenic risk models to surface predispositions to hundreds of conditions including heart disease, diabetes, and cancers, alongside trait predictions. The company has expanded into family planning with Nucleus Preview (carrier screening for couples) and Nucleus Embryo (genetic risk assessment for IVF embryos), working with 165+ clinics globally. Nucleus positions itself as building 'the most predictive genetic models ever built,' aiming to make genomics an actionable, ongoing layer of personal health rather than a one-time report. The company raised a $14M Series A in January 2025 led by returning investors Seven Seven Six and Founders Fund, bringing total funding to roughly $32M, and counts Samsung Next among its strategic backers.